Advertisement
Advertisement
UPB
Upstream Bio, Inc. Common Stock
9.79
USDSponsored
+0.33
+3.54%
Mar 26, 15:59 UTC -4
Closed
Pre-Market
9.14
-0.65
-6.64%
UPB Earnings Reports
Positive Surprise Ratio
UPB beat 1 of 5 last estimates.
20%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$451.47K
/-$0.75
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
-20.23%
/+47.06%
Upstream Bio, Inc. Common Stock earnings per share and revenue
On Mar 18, 2026, UPB reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.70 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 614.41 thousand, with a --% difference.
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.75 USD, with revenue projected to reach 451.47 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Upstream Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Upstream Bio, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Upstream Bio, Inc. Common Stock's Q4 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Upstream Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Upstream Bio, Inc. Common Stock's next earnings report?
Based on 7
analysts, Upstream Bio, Inc. Common Stock is expected to report EPS of -$0.75 and revenue of $451.47K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement